Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors
Open Access
- 29 March 2016
- journal article
- case report
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 71 (7) , 1948-1953
Abstract
Dolutegravir shows a high barrier to resistance with no previously reported cases of acquired integrase mutations during first-line therapy. In this study, rapid development of the G118R mutation arose following a switch from first-line elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine to dolutegravir monotherapy. The G118R mutation also arose in a treatment-experienced patient switched to dolutegravir monotherapy. The genetic basis for G118R selection and potential phenotypic outcome was ascertained. Genotypic analysis was performed on patients with virological failure (in vitro selections were related to a rare GGA natural polymorphism at codon 118 (1.5% prevalence), facilitating a GGA to AGA transition. Cell culture selections were used to assess the in vitro progression of the G118R pathway leading to cross-resistance to all integrase inhibitors. Although resistance to dolutegravir is typically rare, genetic polymorphisms and monotherapy can facilitate the acquisition of G118R.Keywords
Funding Information
- Canadian Institutes of Health Research
- Fonds de Recherche du Quebéc-Santé (FRQS)
- Large-Scale Applied Research Project in Genomics and Personalized Health
This publication has 22 references indexed in Scilit:
- Brief ReportJAIDS Journal of Acquired Immune Deficiency Syndromes, 2015
- Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV PersistenceViruses, 2015
- Dolutegravir inhibits HIV-1 Env evolution in primary human cellsAIDS, 2015
- Differential Effects of the G118R, H51Y, and E138K Resistance Substitutions in Different Subtypes of HIV IntegraseJournal of Virology, 2015
- G118R and F121Y mutations identified in patients failing raltegravir treatment confer dolutegravir resistanceJournal of Antimicrobial Chemotherapy, 2014
- Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy?Viruses, 2014
- Integrase strand transfer inhibitors in the management of HIV-positive individualsAnnals of Medicine, 2014
- Biochemical Analysis of the Role of G118R-Linked Dolutegravir Drug Resistance Substitutions in HIV-1 IntegraseAntimicrobial Agents and Chemotherapy, 2013
- What if HIV were unable to develop resistance against a new therapeutic agent?BMC Medicine, 2013
- Development of Antiretroviral Drug ResistanceNew England Journal of Medicine, 2011